During the first quarter of 2026, Centene Corporation reported $44.7 billion in premium and service revenue for the quarter.

The company also reported a first quarter adjusted diluted EPS of $3.37.

The consolidated HBR was 87.3% for Q1, with the Medicaid HBR at 93.1% and the Medicare segment producing an HBR of 84.9%.

Cash flow provided by operations was $4.4 billion for Q1.Executive leadership noted they are working to "drive margin improvement through targeted and increasingly scaled initiatives to modernize and standardize processes to better manage medical cost trend." In the Marketplace business, Centene gained visibility into demographic and claims experience, forecasting a slight risk adjustment receivable for the year.

Centene is also "deploying advanced analytics and selective AI-enabled tools across forecasting, medical economics and payment integrity" to help "identify fraud, waste and abnormal claims behavior earlier."For forward guidance, Centene updated its projections to "increase our full year 2026 adjusted EPS outlook to greater than $3.40." The company "added $1 billion of premium revenue to our prior range" and expects the "Medicaid composite rate yield around 4.5%," with "no change to our HBR full year range of 90.9% to 91.7%." Additionally, Centene announced leadership changes, noting "Dan Finke joined the organization to serve as our Group President, overseeing the Medicaid and Commercial businesses," and the company elevated "Michael Carson to Group President, overseeing our Medicare PDP and Specialty businesses."

For the first quarter of 2026, SoFi Technologies, Inc. reported that "adjusted net revenue grew 41% to $1.1 billion". Management stated that for the quarter, "adjusted EBITDA was $340 million, up 62% year-over-year" and their "adjusted EBITDA margin for the quarter was 31%". Regarding the first quarter, "Net income in the quarter was $167 million at a margin of 15%" and "Earnings per share were 0.12".TheLendingsegmenthadaparticularlystrongfirstquarter,generating"629 million in adjusted net revenue". The Financial Services segment also delivered impressive quarterly revenue, "up 41% year-over-year to $429 million".During the first quarter, the company "added a record number of new members at 1.1 million new members, increasing total members by 35% year-over-year to 14.7 million". Management noted the effectiveness of their "everything financial services app strategy" and their "ability to build deeper multiproduct relationships with members". This was demonstrated by the fact that "43% of new products opened by existing SoFi members" in the first quarter.

Executives also prioritized "brand building" and noted that "unaided brand awareness rose to an all-time high of 10%" in the quarter.

Regarding products and partnerships, the company noted it "began minting SoFiUSD" and formed an "important partnership with Mastercard to enable SoFiUSD settlement across their global payments network". Management also discussed their "new big business banking offering, which was officially launched earlier this month" and noted they "relaunched SoFi Plus with significantly enhanced benefits" on April 1. Furthermore, the company added "$3.6 billion of new commitments with 3 new partners" to their loan platform business during the quarter, "including a leading global bank, a prominent insurance group and a top 5 global private asset management firm".For the second quarter of 2026, the company expects to deliver "adjusted net revenue growth of approximately 30% from Q2 '25, which would equate to roughly $1.115 billion". Management also anticipates "an adjusted EBITDA margin of approximately 30%, which would equate to roughly $330 million" for the quarter.

Additionally, guidance for the second quarter includes "an adjusted net income margin of approximately 12% to 13%, which equates to roughly $0.10 to $0.11 of EPS". Executives confirmed that their "full year guidance, which remains unchanged" keeps them on track to hit their 2026 targets.

S&P Global Inc. reported that revenue increased 10% year-over-year in the first quarter of 2026, or 9% on an organic constant currency basis.

The company delivered 140 basis points of margin expansion on a trailing 12-month basis and increased adjusted diluted EPS by 14% year-over-year in the first quarter. S&P Global returned $1 billion to shareholders through share repurchases in the quarter.

For the first quarter, the Market Intelligence division revenue grew 8%, Ratings revenue increased 13% year-over-year, Energy revenue grew 7%, Mobility revenue grew 8%, and S&P Dow Jones Indices revenue grew by 17%.

Management highlighted the deployment of AI native solutions and tools, including ChatIQ and Document Intelligence, for customers seeking speed and scale on the CapIQ Pro platform.

The company is completely revamping the Upstream business within the Energy division, which involves an agreement to divest the software portfolio in the second half of 2026 or early 2027 to focus on proprietary Data and Insights.

The planned separation of the Mobility business remains on track, including completion of the spin mid-2026.

For full year 2026 forward guidance, S&P Global is reiterating its enterprise guidance for organic constant currency revenue growth in the range of 6% to 8%.

The company is also reiterating its guidance for 50 to 75 basis points of margin expansion in 2026 excluding the impact of OSTTRA. However, the company currently expects to deliver organic constant currency revenue growth in the range of 4.5% to 6% in the Energy division for the full year, which is 1 percentage point lower than previous guidance, due to the Iran conflict and related energy disruptions.

Management noted they expect to use a combination of incremental share repurchases and debt reduction to increase share repurchases to roughly $4.5 billion for the year.

During the first quarter, the company unveiled a new AI native Upstream product for data and insights called CERA Titan. S&P Dow Jones Indices launched the iBoxx U.S. Treasuries Index as the first major index available as a native digital asset on a blockchain, and launched an additional tokenized S&P 500 Index on blockchain in partnership with Centrifuge. S&P Global also announced a new distribution partnership with SLB.

Teva Pharmaceutical Industries Limited reported Q1 2026 financial results with revenue of $4 billion.

For the quarter, GAAP net income was $360 million, and non-GAAP EPS reached $0.53.

Adjusted EBITDA reached $1.1 billion, and Q1 free cash flow was $188 million.

Non-GAAP gross margin in Q1 2026 was 52.9%, and the non-GAAP operating margin was 24%.

Management discussed continued progress on the Pivot to Growth strategy, highlighting the $700 million upfront cash agreement to acquire Emalex Biosciences.

This acquisition includes ecopipam, a first-in-class asset for pediatric Tourette syndrome.

The company noted that its innovative portfolio continues to drive growth, with Q1 AUSTEDO revenues reaching $559 million in the U.S. and UZEDY Q1 revenues reaching $63 million.

The generics pipeline continues to expand, with 11 biosimilar products currently on the market.

For full year 2026 forward guidance, Teva reaffirmed its 2026 outlook range on an underlying basis, excluding Emalex.

The company expects 2026 non-GAAP gross margin to be in the range of 54.5% to 55.5%, and operating expenses to be toward the higher end of the 27% to 28% range.

Management also reiterated AUSTEDO guidance of $2.4 billion to $2.55 billion for the year.

Teva expects to reach a 30% operating margin target by 2027.In pipeline updates, the company announced the EU submission for olanzapine LAI, which is also currently under FDA review.

Teva completed enrollment for the Phase III FLAIR program for its dual-action rescue inhaler, enrolling over 2,700 patients.

The company also highlighted 44-week maintenance data for duvakitug in ulcerative colitis and Crohn's disease, and anticipates upcoming milestone readouts for its anti-IL-15 program in vitiligo and celiac disease later this year.

For the fiscal second quarter 2026, Visa Inc. reported that "net revenue was up 17% year-over-year to $11.2 billion" and "EPS was $3.31, up 20% year-over-year". Management stated that "payments volume grew 9% year-over-year in constant dollars to $3.7 trillion" and "process transactions grew 9% year-over-year to $66 billion". Additionally, "value-added services revenue grew 27% year-over-year in constant dollars to $3.3 billion". The company also executed the "highest quarterly buyback in Visa's history" by repurchasing $7.9 billion in stock and "distributed $1.3 billion in dividends" during the quarter.

Management outlined four primary drivers for future growth: winning in consumer and commercial money movement, leveraging AI and agentic commerce, utilizing stablecoins and blockchain, and expanding value-added services.

The company positioned itself as a "hyperscaling bridge layer between stablecoin and real-world solutions" with a "$7 billion annual run rate of stablecoin settlement volume" and over 160 stablecoin card programs globally.

Visa is preparing for agentic commerce, where AI agents will intelligently split purchases and create micro transactions, which management believes will "accelerate the digitization of commerce around the world".During the quarter, Visa announced multiple strategic partnerships and product deployments. In the U.K., Visa partnered with TikTok to "launch a debit card specifically designed for content creators". In the U.S., X will utilize Visa Direct and a Visa Flex credential for X money.

The company announced that Wells Fargo "entered into an agreement to migrate to Pismo's core account ledger as part of its core banking modernization". Additional agreements were highlighted with PayPay in Japan, UnionPay International in Mainland China, High Note, Westpac, and Scotiabank.

Management also noted the recent acquisitions of Prisma and New Pay.

For the full year, management increased their guidance, stating they "now expect low double-digit to low teens" net revenue growth and adjusted EPS growth "in the low teens". The company also projected full-year operating expense growth in the "low double-digit to low teens," largely due to increased client demand for FIFA-related marketing services.

For the third quarter, management expects "Q3 net revenue growth in the low double digits", "Q3 operating expense growth in the low teens", and "third quarter EPS growth to be in the mid- to high single digits".

Incyte Corporation reported that "Total revenue in the first quarter of '26 was $1.27 billion" and "Net sales in the first quarter totaled $1.1 billion". Product performance included "Jakafi sales in the first quarter were $758 million", Opzelura "with sales of $143 million", Niktimvo where "Net sales were $55 million in the first quarter of '26", "Monjuvi sales were $49 million in the first quarter", and "Zynyz sales were $41 million in the first quarter". Regarding expenses, "GAAP R&D expenses were $516 million for the quarter" and "GAAP SG&A expenses were $328 million for the quarter".Management highlighted multiple clinical and business updates, noting the FDA accepted the regulatory application for povorcitinib in "moderate to severe HS". The company also announced "positive results from both Phase III registration studies in adults with nonsegmental vitiligo," which "will support a regulatory application in nonsegmental vitiligo expected in the first half of 2027". In Oncology, the company initiated a "Phase III study evaluating our KRAS G12D inhibitor '734 in combination with chemotherapy in first-line pancreatic ductal adenocarcinoma". Additionally, Zynyz "was approved by the European Commission for patients with previously untreated squamous cell anal carcinoma". Incyte also announced the executive appointments of "Suky Upadhyay as Chief Financial Officer", "Pablo Cagnoni as President Incyte and Global Head of Research and Development", "Steven Stein as Executive Vice President, Chief Medical Officer", and "Mohamed Issa was appointed as Executive Vice President and Head of U.S. Commercial".Executives shared their strategic focus to "transition Incyte beyond a single cornerstone product toward a high-quality growth-oriented portfolio across Hematology, Oncology and Immunology". Management reaffirmed their forward guidance, stating "Total net sales guidance for the full year 2026 is $4.77 billion to $4.94 billion". This full year guidance includes "net sales expectations for Jakafi of $3.22 billion to $3.27 billion, Opzelura of $750 million to $790 million and Hematology and Oncology products of $800 million to $880 million". Finally, "Total GAAP R&D and SG&A operating expenses are expected to be $3.495 billion to $3.675 billion for the full year".

During the first quarter of 2026, Union Pacific Corporation reported that "operating revenue of $6.2 billion increased 3% versus last year" and "freight revenue of $5.9 billion grew 4%". Management noted that "reported net income of $1.7 billion grew 5%" and "earnings per share of $2.87 increased 6%" for the quarter.

The company's adjusted "operating ratio came in at 59.9%". Additionally, the company "generated free cash flow of $630 million" for the first quarter.

Management highlighted several key business updates, emphasizing operational efficiency.

The company achieved "best-ever terminal dwell of 19.7 hours" and reported that "freight car velocity increased 9% to 235 miles per day". Executives also noted that "workforce productivity, which includes all employees, increased 7%" and "locomotive productivity improved 6%". Regarding corporate strategy, management stated they are "100% on track with filing a revised application on April 30" for an ongoing merger process.

Looking ahead, Union Pacific is "affirming our 2026 outlook", which includes expectations for "reported earnings per share of mid-single-digit growth and operating ratio improvement" for the full year.

For the longer term, the company remains "committed to attaining our 3-year CAGR target of high single-digit to low double-digit EPS growth throughout 2027". Management also highlighted business development momentum, mentioning "expansion into Mexico, such as Bartlett's new facility in Monterrey", winning "incremental volume with BMW", and the upcoming third-quarter start-up of the "Golden Triangle Polymers Company joint venture with CPChem".

During the first quarter of 2026, NextEra Energy, Inc. reported that "Adjusted earnings per share increased by 10% year-over-year". Florida Power and Light Company reported its first quarter 2026 earnings per share increased $0.06 year-over-year, with capital expenditures of approximately $3.2 billion for the quarter.

Energy Resources reported adjusted earnings growth of approximately 14% year-over-year for the quarter.

Adjusted earnings from Corporate and Other decreased by $0.02 per share year-over-year for the quarter.

Management provided key business updates, emphasizing that "demand for electricity in this country is not slowing down. In fact, it's accelerating". Florida Power and Light Company added nearly 100,000 customers in the first quarter compared to the prior year comparable period.

Energy Resources achieved a record quarter by adding 4 gigawatts of new long-term contracted renewables and storage projects to its backlog.

The company also advanced its growth strategy with the strategic acquisition of Symmetry Energy Solutions, one of the leading natural gas suppliers in the U.S.. Additionally, the company is executing its data center hub strategy and working with hyperscalers on a bring your own generation model.

Regarding forward guidance, NextEra Energy's 2026 adjusted earnings per share expectations range of $3.92 to $4.02 remains unchanged.

The company expects to grow adjusted earnings per share at a compound annual growth rate of 8% plus through 2032 from a 2025 base of $3.71 adjusted earnings per share.

The company also continues to expect to grow dividends per share at roughly 10% per year through 2026 off a 2024 base, and 6% per year from year-end 2026 through 2028.

Florida Power and Light Company expects full-year capital investments to be between $12 billion and $13 billion and anticipates investing between $90 billion and $100 billion through 2032.

The company announced several notable partnerships and product initiatives.

The U.S. Department of Commerce selected Energy Resources to build 9.5 gigawatts of new gas-fired generation in connection with a U.S.-Japan trade deal.

NextEra Energy also highlighted a joint development agreement with Excel to deploy new generation, storage, and transmission across an 8-state service territory.

The company launched its new Rewire initiative and a partnership with Google Cloud, introducing AI products such as Conduit, Generation Entitlement, and Grid Composer.

Management also noted a collaboration with NVIDIA focused on dispatchable power solutions during extreme demand.

Freeport-McMoRan Inc. reported that sales of copper, gold and unit costs were better than forecast in the first quarter of 2026.

The company generated growth in revenues, EBITDA and cash flow compared with last year's first quarter.

Management stated that U.S. mining operations contributed 2.5x more operating income in the first quarter of this year compared with last year's first quarter.

The company reached an agreement with insurance providers for a $700 million insurance recovery and returned approximately $300 million to shareholders in the first quarter.

The company completed the required remediation at Grasberg to commence a phased ramp-up in production blocks 2 and 3. During the quarter, the company identified material handling bottlenecks downstream of the extraction level at Grasberg due to an increase in wet ore, with 45 percent of active draw points currently wet compared to 30 percent in September 2025. To address this, the company is installing specialized equipment to regulate the flow of ore for train loading. In the U.S., the company achieved a 19 percent increase in mining rates at Morenci compared with last year's first quarter.

The company expects net unit costs to average $1.95 per pound of copper for the year, updated from a prior estimate of $1.75 per pound.

The revised 5-year production forecast for the Grasberg district reflects an approximate 9 percent reduction for copper and 7 percent for gold.

For the second half of the year, volumes are expected to be approximately 30 percent higher for copper and approximately 50 percent higher for gold compared with the first half.

Capital expenditures are expected to approximate $4.3 billion in 2026 and $4.5 billion in 2027.

The company reached a memorandum of understanding in February with the Government of Indonesia to extend operating rights for the life of the resource. In March, the company submitted an environmental impact statement for a major expansion at the El Abra project in Chile in partnership with CODELCO. The company also commenced a pilot test at Morenci to increase the temperature of stockpiles by applying a heated leaching solution, aiming to scale this innovative leach initiative to 300 million to 400 million pounds per annum in the 2026 to 2027 time frame.

Novartis AG reported first quarter 2026 financial results with "sales down 5% and core op inc down 14%". Management noted that the "Core margin in Q1 declined 4.1%" due to higher research and development investments and the impact of generics on the gross margin.

Despite the overall decline in the first quarter, executives emphasized that "growth drivers were up 34% in constant currency". The company also reported that first quarter free cash flow was broadly in line with the previous year's first quarter, and they paid a $9.1 billion dividend in March and April.

Management highlighted a strong start to the first quarter across priority brands and launches.

Executives stated that "Kisqali grew 55%" driven by momentum in early and metastatic breast cancer.

The company noted Kesimpta had a 26 percent growth, outpacing the market, while Pluvicto United States sales grew 76 percent in the first quarter.

Additionally, "Scemblix was up 79%" and Leqvio saw 31 percent growth in the United States alongside 106 percent constant currency growth outside of the United States.

During the first quarter, Novartis AG completed its acquisition of Avidity, adding three late-stage medicines for neuromuscular disease to its pipeline.

The company also announced two early-stage deals intended to support its oncology and immunology disease franchises. In terms of capital allocation, management noted they continue to progress with an up to $10 billion share buyback program, with around $6.1 billion remaining to be completed by the end of 2027.

For forward guidance, the company reaffirmed its full year 2026 expectations.

For the full year 2026, Novartis AG anticipates low single-digit sales growth and a low single-digit decline in core operating income.

The core net financial expense for the full year 2026 is projected to be around $1.7 billion and the core tax rate will be about 16.5 percent.

Management expects second quarter sales to decline low single digits and core operating income to decline high single digit to low double digit, before seeing a second half sales growth of mid-single digit and core operating income growth of mid- to high single digits.